|
TG's shares shot up 63.5 percent to $8.75 in premarket trading.
The late-stage study involved adult patients with high-risk chronic
lymphocytic leukemia, who had undergone at least one prior therapy.
The study was designed to show that adding ublituximab would induce
a statistically significant improvement in overall response rate by
at least 20 percent between the two trial arms.
The absolute difference between the two groups of patients was about
30 percent, the company said.
TG said it would meet with the U.S. Food and Drug Administration to
chart a path toward accelerated approval.
In 2015, AbbVie forked out $21 billion for Pharmacyclics, giving it
joint ownership of the blockbuster leukemia treatment, Imbruvica,
with Johnson & Johnson.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina
D'Couto)
[to top of second column] |
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
